Argentina vs Kyrgyzstan: Average cost of multi drug-resistant tuberculosis treatment
Argentina
1,547 constant 2022 US$
in 2024
Kyrgyzstan
1,607 constant 2022 US$
in 2022
Argentina rank
31st
Kyrgyzstan rank
29th
Average cost of multi drug-resistant tuberculosis treatment over time
- Argentina
- Kyrgyzstan
How they compare
Kyrgyzstan currently reports 1,607 constant 2022 US$ against 1,547 constant 2022 US$ in Argentina, a difference of 60 constant 2022 US$.
The two have swapped places 3 times across 6 shared years of data; in 2017 it was Argentina ahead.
Argentina ranks 31st and Kyrgyzstan ranks 29th of 92 countries.
Across the 2 decades both report, Argentina averaged higher in 1 and Kyrgyzstan in 1.
Head to head by decade
| Decade | Argentina | Kyrgyzstan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 3,035 constant 2022 US$ | 2,218 constant 2022 US$ | 817 constant 2022 US$ | Argentina |
| 2020s | 1,463 constant 2022 US$ | 1,761 constant 2022 US$ | 297.33 constant 2022 US$ | Kyrgyzstan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Argentina or Kyrgyzstan?
- Kyrgyzstan, at 1,607 constant 2022 US$ against 1,547 constant 2022 US$ in Argentina as of 2022.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Argentina and Kyrgyzstan?
- 60 constant 2022 US$, with Kyrgyzstan ahead.
- How many years of comparable data are there for Argentina and Kyrgyzstan?
- 6 years are reported by both, from 2017 to 2022.
- How do Argentina and Kyrgyzstan rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Argentina ranks 31st and Kyrgyzstan ranks 29th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.